Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will support a lead program zolucatetide, which is in development for a rare type of tumor with limited treatment options.
The post Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO appeared first on MedCity News.
